1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Guangzhou LBP Medicine Science & Technology Co., Ltd. Class A

Guangzhou LBP Medicine Science & Technology Co., Ltd. Class A

SSSE:688393
19.18
CNY
+0.35
(+1.86%)
-0.43EPS
1.66BMarket Cap
Oct 31Next Earn
Guangzhou LBP Medicine Science & Technology Co., Ltd. Class A
SSE:688393
(Shanghai Stock Exchange)

Recent

price

19.18

P/E

ratio

- -

div

yld

0.01%

ROIC.AI

2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
8.76
1.55
2.04
3.46
3.72
4.38
5.09
4.83
4.68
5.47
5.34
5.09
3.66
3.76
Revenue per Share
2.71
0.4
0.55
0.66
0.69
0.88
1.06
1.09
0.85
0.46
0.43
0.23
-0.5
-0.4
Basic EPS, GAAP
-2.12
-0.15
-0.79
0.4
0.72
0.31
0.78
0.37
-0.89
-0.67
-0.22
-0.22
0.18
- -
Free Cash Flow per Basic Share
- -
- -
- -
0.14
0.3
0.24
0.28
- -
0.28
0.29
0.14
0.16
0.1
- -
Dividend per Share
0.69
2.48
3.03
4.51
4.9
5.53
6.33
12.51
12.9
13.16
13.5
13.42
12.65
12.15
Book Value per Share
0.68
2.47
2.93
4.32
4.72
5.32
6.13
12.36
12.52
12.77
12.98
12.79
11.92
11.34
Tangible Book Value per Share
10
69
70
70
70
70
70
78
94
93
93
93
94
93
Basic Weighted Avg Shares
88
107
143
241
260
306
355
375
439
507
497
471
344
350
Sales/Revenue/Turnover
31.59
27.57
27.43
20.06
23.02
24.38
24.85
25.5
15.27
6.23
4.06
2.28
-15.85
-10.39
Operating Margin (%)
3
3
5
12
13
12
11
10
19
36
41
41
43
- -
Depreciation Expense
27
28
38
46
48
61
74
85
80
43
40
21
-47
-37
Net Income, GAAP
14.59
14.11
13.19
15.22
17.2
16.18
16.56
16.25
15.15
- -
- -
- -
- -
- -
Effective Tax Rate (%)
30.95
25.81
26.95
19.09
18.56
20.07
20.83
22.57
18.17
8.41
8.06
4.52
-13.65
-10.55
Profit Margin (%)
37
155
137
233
272
274
308
976
802
481
457
608
529
503
Working Capital
- -
- -
- -
- -
- -
- -
- -
2
3
7
5
2
1
1
LT Debt
48
173
215
321
346
389
445
1,168
1,210
1,222
1,238
1,232
1,159
1,133
Total Equity
- -
22.02
17.28
14.38
15.11
17.31
18.14
10.53
6.39
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
25.05
19.3
16.56
13.99
16.46
17.92
10.01
7.07
- -
- -
- -
- -
- -
Return on Capital (%)
- -
25.05
19.96
17.46
14.69
16.85
17.83
10.52
6.73
3.51
3.21
1.69
-3.85
-3.1
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
94
94
94
Market Capitalization
2,217
2,202
1,664

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
612
587
573
Cash, Cash Equivalents & STI
266
300
287
Accounts Receivable, Net
177
168
158
Inventories
90
98
106
Total Current Liabilities
83
62
70
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.6%
-0.09%
-5.87%
Free Cash Flow
-68.57%
-133.55%
-183.9%
Net Income, GAAP
-33.94%
-85.25%
-320.86%
Sales/Revenue/Turnover
11.47%
-0.33%
-26.84%
Total Cash Common Dividend
- -
- -
-34.29%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
101
127
125
118
471
2025
73
87
- -
92
344
2026
80
92
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.09
0.14
-0.09
0.23
2025
-0.12
-0.02
- -
-0.39
-0.5
2026
-0.02
0.03
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.15
0.02
-0.02
0.16
2025
- -
- -
- -
- -
0.1
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Guangzhou LBP Medicine Science & Technology Co., Ltd. is a leading enterprise in China’s pathological diagnosis sector, focusing its efforts on the research, development, and commercialization of advanced in vitro diagnostic solutions. The company provides a wide array of pathological diagnostic reagents and specialized instruments, primarily engineered for tumor screening and precise disease identification. Its comprehensive offerings span across several critical technological platforms. These include advanced liquid-based cytology products, encompassing both gynecological and non-gynecological applications, alongside their accompanying automated equipment. The portfolio also features fluorescence in situ hybridization (FISH) items designed for the detection of various cancers such as breast, bladder, lung, and cervical, as well as indications in hematologic malignancies and prenatal screening. Additionally, LBP Medicine Science & Technology delivers robust immunohistochemistry solutions, including a broad range of antibodies, detection, and repair systems. The company also offers molecular genetic diagnosis products and has expanded into digital pathology and artificial intelligence solutions. Founded in 2005 and headquartered in Guangzhou, China, the firm operates with a dual-driven model, combining product innovation with extensive service offerings such as smart pathology department infrastructure and capability enhancement initiatives.